The Wegovy pill market is no longer in the launch phase. More UK providers are now showing live oral semaglutide pages, while the official guidance around semaglutide and GLP-1 medicines keeps moving. That makes the job for readers simpler in one sense and harder in another: the key question is no longer whether the tablet exists, but which provider is current, which price is standard and which wording is still out of date.
What has changed in the live tracker
At the time of writing, the live CompareWegovyPrices tracker includes current Wegovy pill listings from Boots, Numan, Pharmacy2U and Superdrug, alongside other active providers. That matters because the market is now wide enough for a real comparison, but still fluid enough that older launch language can linger on individual pages.
We are still seeing a mix of page states across the wider market. Some providers publish straight dose pricing, some publish consultation-led routes and some still add offer or bundle language that needs to be read separately from the standard price row. The comparison table is still the cleanest way to separate those things.
The guidance side is also moving
NICE TA1152, published on 7 May 2026, added an evidence-based recommendation for semaglutide (Wegovy) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. That does not change private prescribing rules, but it does matter for how the medicine is discussed.
NHS England’s interim commissioning guidance for tirzepatide continues to phase access in primary care, with access widening over time through prioritised cohorts. The practical point for readers is that NHS access remains structured and limited, so private provider pages still have to be read carefully.
Safety updates and what changed
On the safety side, the MHRA’s January 2026 Drug Safety Update strengthened warnings around acute pancreatitis, including rare severe cases. The agency also states that the available evidence does not support a causal association between GLP-1 medicines and suicidal ideation or suicide in its current public information on GLP-1 medicines.
Those two points are worth keeping together. They do not change the fact that these are prescription medicines used under clinical supervision, but they do explain why this site keeps safety language separate from pricing language.
What the trial data says about semaglutide and tirzepatide
The recent head-to-head SURMOUNT-5 data also remains relevant for readers comparing treatment classes. Eli Lilly’s press materials and the later NEJM publication reported that tirzepatide produced greater average weight loss than semaglutide in the study population, with both medicines still requiring clinical assessment and prescriber oversight.
That does not make one treatment automatically right for every reader. It does mean the comparison pages need to stay current, because clinical headlines and provider pages are both moving targets.
What this means if you are comparing prices
If you are checking Wegovy pill providers today, start with the live table and then open the provider page for the dose you actually need. The cleanest signal is still the public price row, the latest checked date and the provider’s current route wording. If any of those are stale, treat the page cautiously. For a closer look at how much prices have actually shifted this year, see why Wegovy prices have moved so much in 2026, including a directly checked example from one major provider.
For readers who want the short version: the market is active, the guidance is still evolving and the safest way to compare providers is to read the dated tables first, then decide whether a provider page is current enough to trust.
